Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2023 | $15.00 | Hold → Buy | Jefferies |
| 8/7/2023 | $30.00 | Hold → Buy | Maxim Group |
| 7/22/2022 | Outperform → Neutral | Robert W. Baird | |
| 7/22/2022 | Buy → Hold | Jefferies | |
| 7/22/2022 | Outperform → Mkt Perform | William Blair |
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
SCHEDULE 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
Jefferies upgraded VistaGen from Hold to Buy and set a new price target of $15.00
Maxim Group upgraded VistaGen from Hold to Buy and set a new price target of $30.00
Robert W. Baird downgraded VistaGen from Outperform to Neutral
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation at the Stifel Healthcare Conference on Wednesday, November 12 from 3:20-3:50 p.m. Eastern Time. The Company will also host one-on-one meetings during the conference. A live webcast will be accessible through the "Events" page in the "Investors" section of the Company's website at www.Vistagen.com. A replay of the webcast will be archived and available f
Topline results for the trial are expected by year end Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the last patient has completed the randomized, double-blind, placebo-controlled portion of the PALISADE-3 Phase 3 clinical trial evaluating fasedienol for the acute treatment of social anxiety disorder. The open label extension of the study is currently ongoing. "The completion of the PALISADE-3 Phase 3 public speaking challenge study marks an important milestone for Vistagen," said Shawn Singh,
Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors ("Board"). Following the appointment of Mr. Edick, Vistagen's Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. "We are pleased to welcome Mr. Edick to our Board of Directors," said Maggie FitzPatrick,
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
3 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of 2025 PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Vistagen continues to advance diverse intranasal pherine pipeline targeting treatments in psychiatry, women's health, and cancer supportive care Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 first quarter ended June 30, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at least 1
Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of this year PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Company showcases promising clinical-stage pipeline of five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corp
Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors ("Board"). Following the appointment of Mr. Edick, Vistagen's Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. "We are pleased to welcome Mr. Edick to our Board of Directors," said Maggie FitzPatrick,
Accomplished biopharma executive brings nearly 30 years of experience in business development, enterprise strategy, and global partnerships to her role Ms. Cote to help drive the strategic positioning of Vistagen's clinical-stage pipeline, which includes five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead t
Vistagen CEO Shawn Singh; The Goldie Hawn Foundation Founder Goldie Hawn; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join toget
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)